Fluorine-Containing Anticancer Compounds as Stable Solid Salts
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing AKR1C3 enzyme-activated DNA alkylating agents, which are yellow oils, face challenges in purification due to complex and costly processes, stability issues, and limited dosage form options, making them inconvenient for storage, transport, and administration.
Innovation Solution
Structurally modified fluorine-containing compounds are synthesized to convert the oils into solid salts, introducing fluorine-containing groups at specific positions to maintain enzyme activation while facilitating solid formulation and metering.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the compounds are kept as yellow oils (original form), then the AKR1C3 enzyme activation and cancer cell killing effects are maintained, but the purification process becomes complicated and costly, and the formulation is inconvenient with poor stability
Solution Approach 1:
The patent applies parameter changes by converting the physical state of the compounds from liquid oils to solid salts through salt formation with pharmaceutically acceptable acids. This phase change enables the use of efficient solid-state purification methods like recrystallization and slurry purification, replacing complex column chromatography while maintaining the core enzymatic activation functionality.
Solution Approach 2:
The invention utilizes phase transitions by transforming the compounds from liquid oil phase to solid salt phase. This transition fundamentally changes the purification approach available, enabling low-cost recrystallization and slurry techniques that are ineffective for liquid oils, thereby resolving the manufacturing complexity issue.
2Stability of the object's composition
If the compounds are kept as yellow oils, then the original structure is preserved, but the formulation is inconvenient for transport and metering, and dosage form options are limited
Solution Approach 1:
The patent introduces pharmaceutically acceptable acid salts as intermediary forms that bridge the original oil compound and the final dosage form. These salt forms serve as stable intermediates that are easier to handle, transport, and formulate while maintaining the ability to regenerate the active parent compound in vivo through physiological conditions.
Solution Approach 2:
By changing the physical state parameter from liquid to solid through salt formation, the patent improves handling convenience, transportability, and metering accuracy. The solid salt forms enable diverse dosage form development including tablets, capsules, and injectables, which are impractical with liquid oil forms.
3Manufacturing precision
If column chromatography is used for purification of oil compounds, then the compounds can be purified, but the operation becomes complex and costs increase
Solution Approach 1:
The patent resolves this contradiction by changing the physical state parameter from liquid to solid, which fundamentally alters the available purification techniques. Solid salts enable simple recrystallization and slurry purification methods that achieve high purity without requiring complex column chromatography apparatus and procedures.
Solution Approach 2:
The phase transition from liquid oil to solid salt enables the use of gravity-based solid-liquid separation techniques and recrystallization methods, replacing the need for chromatographic separation. This dramatically simplifies the purification operation and reduces equipment complexity while maintaining high manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified compounds exhibit strong cancer cell inhibition activity in vitro and can be formulated into various dosage forms, enhancing stability and administration convenience while maintaining high tumor selectivity.
Implementation Method 1
these compounds, as specific substrates of the aldo-keto reductase AKR1C3, can be quickly and effectively reduced only in cancer cells which overexpress AKR1C3, thereby releasing cytotoxins
Data Source
AI summary
The present invention provides a fluorine-containing compound shown in Formula II/III and its anti-cancer medical use.